Structural Biomarkers for Kidney Injury
Structural (damage) biomarkers for kidney injury include molecules that indicate actual tubular cell damage and tissue injury, distinct from functional markers like serum creatinine that only reflect filtration changes. These biomarkers detect structural kidney damage that may occur before or independently of functional decline 1.
Key Structural/Damage Biomarkers
The 2020 ADQI consensus guidelines categorize the following as validated structural damage markers 1:
Urinary Damage Markers
- Kidney Injury Molecule-1 (KIM-1): Released from damaged proximal tubular cells; demonstrates high sensitivity and specificity for tubular injury 2, 3
- Neutrophil Gelatinase-Associated Lipocalin (NGAL): Rises within hours of tubular damage, detectable in both urine and serum before creatinine elevation 2, 4
- Netrin-1: A 50-75 kDa molecule minimally expressed in normal kidneys but released into urine after tubular cell damage 1
- N-acetyl-β-D-glucosaminidase (NAG): Enzyme released from damaged tubular cells 3
- Clusterin: Protein marker of tubular injury with established thresholds for detecting AKI 3
Plasma/Urinary Dual Markers
- Osteopontin: Glycoprotein expressed in tubular cells and interstitial areas of tubulointerstitial damage; functions as both stress and damage marker 1, 3
- Cystatin C: While primarily a functional marker, elevated urinary cystatin C indicates tubular dysfunction and damage 5, 2
Reabsorption Dysfunction Markers
- Retinol Binding Protein: Released into urine following proximal tubular damage affecting reabsorption 1
- Alpha-1-microglobulin: Marks tubular cell dysfunction 6
Critical Distinction: Damage vs. Stress vs. Functional Markers
The ADQI guidelines emphasize that damage biomarkers indicate actual structural injury, which is fundamentally different from stress markers (like TIMP-2 and IGFBP7 that indicate cell cycle arrest) or functional markers (like creatinine that reflect filtration) 1. This distinction matters clinically because:
- Patients can have elevated damage biomarkers without creatinine changes, indicating subclinical structural injury associated with worse outcomes 1
- Conversely, creatinine elevation without damage marker elevation may represent prerenal azotemia rather than true kidney injury 1
Clinical Application Framework
The consensus strongly recommends combining damage biomarkers with functional markers and clinical assessment rather than using any single marker in isolation 1. The proposed approach:
Risk Stratification: Use damage biomarkers to identify patients with structural injury who are at higher risk for progression to functional AKI or chronic kidney disease 1, 7
Early Detection: Damage markers detect injury hours to days before serum creatinine rises, enabling earlier intervention 1, 2
Prognostic Assessment: Elevated damage biomarkers at ICU discharge predict long-term mortality and CKD development even when creatinine has normalized 1
Therapeutic Monitoring: Serial damage biomarker measurements can guide interventions and assess treatment response 1, 8
Established Thresholds
For clinical decision-making, validated thresholds exist for several markers 3:
- KIM-1: 4.3-fold increase (statistically significant), 7.5-fold (medically significant for AKI)
- NGAL: 2.9-fold increase (statistically significant), 7.8-fold (medically significant)
- Clusterin: 2.2-fold increase (statistically significant), 5.1-fold (medically significant)
- NAG: 2.7-fold increase (statistically significant), 8.1-fold (medically significant)
These represent fold-changes from baseline when normalized to urine creatinine 3.
Important Caveats
Sex differences significantly affect reference intervals for most damage biomarkers, requiring sex-stratified interpretation 5. Age, BMI, and common comorbidities have minimal effect on most markers 5.
The evidence base shows that damage biomarkers outperform eGFR changes for early detection of kidney injury, but their predictive value for long-term mortality remains modest (AUROC 0.61-0.70) 1. This underscores that these markers are most valuable when integrated into comprehensive clinical assessment rather than used as standalone predictors.
The field continues to evolve, with ongoing validation needed for optimal cutoffs, timing of measurements, and combinations of markers that best predict patient-centered outcomes including mortality, need for dialysis, and progression to CKD 1.